ABSTRACT
Background: There is evidence of persistent symptoms after COVID-19 disease in more than 50 %. of patients (pts.). We hereby report our experience with lung function tests in Post-COVID pts. in an outpatient clinic. Method(s): Since spring 2020, we offered ambulatory control of lung function and imaging after COVID-19 disease. Lung function tests (LFT) including blood gas analysis were performed. Result(s): 66 consecutive pts. (39M, 27F, age 50+/-15.1 Y, BMI 29+/-6 kg/m2) without pulmonary pre-existing condition presented with persistent symptoms 168+/-122 days after COVID. 41 pts. were treated ambulatory and 25 pts. were hospitalized (none with prolonged ventilation). LFT's were normal (TLC 99+/-18 %, VC 91+/-20 %, FEV1/VC 80+/-10 %, pO2 86+/-10 mmHg, pCO2 37+/-4 mmHg), except in 6 pts., where LFT was slightly impaired: 2 showed moderate obstruction and 4 a restrictive pattern. Interestingly 22 pts. (34.9%) presented with a low pCO2, indicating different degrees of HV, inclining in F (M 7/39 vs. F 15/27, p=0.004). Also, 12 pts. with known pulmonary precondition diagnoses (6 sarcoidosis, 2 chronic hypersensitivity pneumonitis (HP), 1 non-specific interstitial pneumonia, 1 CTD-ILD, 1 asthma, 1 organizing pneumonia (OP) by primary biliary cirrhosis) presented after COVID-19 disease. In 8 of these pts. the LFT was comparable as before COVID-19 disease. One patient with HP showed prolonged recovery, one asthmatic needed intensified treatment, and one presented with a new episode of OP. Discussion(s): Our pts., who recovered from mild to moderate COVID-19 disease, presented with good prognosis with regard to LFT. HV could be one pathophysiologic mechanism for Post-COVID symptoms, particularly in F.
ABSTRACT
Aim/Introduction: Airborne infections are particularly challenging for in-patient care units. In general, hospitals take more precautions to prevent airborne spread of diseases and several guidelines recommend expiratory filters during nebulizer therapies to reduce exhaled bioaerosols. However, a substantial reduction of virusloaded aerosols depend on a high filter performance for particles 100 -500nm in size. This study aimed to test the effectiveness of filter pads in the reduction of exhaled aerosols by applying 99mTclabeled graphite aerosol. Material(s) and Method(s): In 37 patients with suspected pulmonary embolism or CTEPH an inhalation scintigraphy was performed with 99mTc-labeled graphite aerosol (Technegas ©, particle size 30 -60nm ). The exhalate was filtered by a PARI filter/valve set equipped with a PARI filter pad and then collected in a plastic bag reservoir. Count rates of the filter pads and reservoirs were estimated by planar imaging within a SPECT/ CT. In addition, the individual volumes of the exhaled air were determined. The percentage filter efficacy of the filter pads was calculated. Finally, correlational statistics (Spearman's correlation) addressing the following interactions were performed: (1) exhalate volume and count rates of the filter pads, (2) filter pads' count rates and filter retention efficacy, and (3) exhaled breath volume and filter retention efficacy. Result(s): Mean count rates of the filter pads and the reservoirs containing the filtered exhalate were 26023 +/- 8327 cts/s and 169 +/- 153 cts/s, respectively. The efficacy of the PARI filter/ valve set with PARI filter pad was 98.5 +/- 0.9% (range 96.2 -99.7%). The mean exhaled volume was 9.5 +/- 4.6 l (range 2.4 -21.0 l). The exhalate volumes positively correlate with the filter pad count rates (p=0.006) which, in turn, negatively correlate with the filter pad efficacy (p=0.04). However, an inter-relation of exhaled breath volume and filter pad efficacy failed to reach significance (p=0.07). Conclusion(s): The filter pad of the PARI filter/valve set demonstrated a high retention rate of aerosol particles < 100nm in size. Therefore, in patients suffering from respiratory infections these filter pads used in expiratory filters are suitable to substantially reduce airborne virus load, e.g. COVID-19 SARS CoV2, in their exhalates. Additionally, we found evidence that the filter retention efficacy decreased with increased filter particle load indicating a need for regular filter changes.
ABSTRACT
Objectives: The aim of this ongoing longitudinal study is to examine the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on aspects of physical fitness (PF, strength endurance, explosive power, coordination under time pressure, coordination for the precision aspect, trunk flexibility, peak workload, habitual physical activity (HPA, steps/day, intensity), and zscores of FEV1 and BMI in children with cystic fibrosis (CF)). All children have been receiving ELX/TEZ/IVA for 19.2 ± 10.4 (11–33) months. Methods: Six children with CF agreed to participate (3f/3 m) mean age 13 ± 4yrs (9–17 yrs), FEV1 z-score − 1.017 ± 1.817 (-3.2–0.8). PFwas assessed using 5 test items at baseline and 4.51 ± 0.98 years later;strength endurance (PU push-ups, SU sit-ups), explosive power (SLJ standing long jump), coordination under time pressure (JSS jumping side to side), coordination for the precision aspect (BB balancing backward on beams), and trunk flexibility (FB, forward bend). Cycle-ergometry (Godfrey-protocol) was used to determine Wpeak. Lung function was measured by spirometry. Results: Significant improvements were seen in test items representing strength endurance (PU, SU) and coordination under time pressure (JSS) (p < .05). Although HPA expressed as steps/day remained the same, thetime of moderate to vigorous intensity of HPA decreases significantly (p < .05). A slight, not significant, improvement of BMI Z-score was observed (p > .05). No or small changes could be observed for the parameter FEV1 z-score, Wpeak, PF, SLJ, BB and FB (p > 0.05). Conclusion: ELX/TEZ/IVA therapy seems to be a facilitator to increase some aspects of PF. The decrease in intensity of HPA is possibly an effect of the COVID-19 Pandemic that has already been described in healthy and asthmatic children. In this ongoing study, we assume that clearer effects will be shown with a greater number of children included. However, ELX/ TEZ/IVA enhanced muscle strength endurance in children with CF.
ABSTRACT
Background: Vaccinations against Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are intended to induce an immune response in the sense of protection against infection/disease. Allergen-specific immunotherapy (AIT) is also thought to induce a (different) immune response in the sense of tolerance to allergens. There is uncertainty among patients and physicians regarding the use of vaccination and AIT in temporal relation, which this position paper aims to clarify. The four vaccines currently approved in Germany for vaccination against SARS-CoV-2 are described and possible immunological interactions with AIT are highlighted, as well as practical recommendations for action. Methods: Based on the current internationally published literature, this position paper provides specific recommendations for action regarding the use of AIT in temporal relation to a SARS-CoV-2 vaccination. Results: The present recommendations for action relate to the following conditions for which AIT is used i) allergic rhinitis, ii) allergic bronchial asthma, iii) insect venom allergy, iiii) food allergy (peanut). Conclusions: If vaccination is imminent, initiation of subcutaneous (SCIT), sublingual (SLIT), or oral (OIT) AIT should be delayed until 1 week after the 2nd vaccination date. Thus, there should generally be an interval of approximately 1 week between SCIT and COVID-19 vaccination. For the continuation of an ongoing AIT, we recommend an interval of 1 week before and after vaccination for SCIT. For SLIT and OIT, we recommend taking them up to the day before vaccination and taking a break from SLIT and OIT for 2 – 7 days after vaccination.
ABSTRACT
Patients with asthma should be vaccinated against COVID-19. This includes patients with severe asthma. Treatment with a biological for asthma is no contra-indication for vaccination against COVID-19.
Subject(s)
Asthma , COVID-19 , Pulmonary Medicine , Asthma/drug therapy , Austria , COVID-19 Vaccines , Humans , SARS-CoV-2 , VaccinationABSTRACT
Introduction: To date, 23 lung transplant recipients have been described with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections worldwide. Eight had severe coronavirus disease 2019 (COVID-19), but none were placed on extracorporeal membrane oxygenation (ECMO) support. We aimed to describe our experience. Methods: Lung transplant recipients who were admitted to our hospital with SARS-CoV-2 infections from the beginning of the pandemia until May 25th, 2020 were included. Clinical charts were retrospectively retrieved and data analysed. Results: Four patients (3 males, 75%) with a median age of 58.5 years (47-66) were admitted for SARS-CoV-2 infections in our center. Three patients had double-lung transplantation for chronic thromboembolic pulmonary hypertension, idiopathic pulmonary fibrosis and cystic fibrosis. One patient had singlelung transplantation for non-specific interstitial pneumonia. SARS-CoV-2 infections were diagnosed by nasopharyngeal swabs in all patients within one month post-transplant (n=2), or after 13 months (n=1) and 15 years (n=1). Dyspnea was present in all patients. Worsening of symptoms occurred in three patients after a median of 8 days (1 to 8) after diagnosis. Imaging showed a highly variable degree of infiltrations. Mechanical ventilation was required in three patients. They all underwent prone positioning. Veno-venous ECMO was required in two patients. In all patients, immunosuppression consisted of prednisone and tacrolimus, while mycophenolate mofetil was stopped. Treatment with hydroxychloroquine was attempted in the first three patients. At last follow-up, one patient was discharged home and one was weaned from mechanical ventilation. Both ECMO supported patients died from multiple organ failure, despite ECMO could be weaned in one patient. Conclusion: A highly variable course of COVID-19 disease was observed in four patients after lung transplantation. More data is needed to better understand prognostic factors and management of this patient cohort.